HER2 and Central Nervous System Metastasis in Patients with Breast Cancer

Kim, 2001, HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation, Clin Cancer Res, 7, 4008 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Bendell, 2003, Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma, Cancer, 97, 2972, 10.1002/cncr.11436 Seidman, 2001, Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification, J Clin Oncol, 19, 2587, 10.1200/JCO.2001.19.10.2587 Esteva, 2002, Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer, J Clin Oncol, 20, 1800, 10.1200/JCO.2002.07.058 Montemurro, 2004, A phase II study of threeweekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer, Oncology, 66, 38, 10.1159/000076333 Pestalozzi, 2000, Trastuzumab in CSF, J Clin Oncol, 18, 2349, 10.1200/JCO.2000.18.11.2349 Miller, 2003, Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival, Ann Oncol, 14, 1072, 10.1093/annonc/mdg300 Fornier, 2002, HER2 testing and correlation with efficacy of trastuzumab therapy, Oncology (Huntingt), 16, 1340 Lear-Kaul, 2003, Her-2/neu status in breast cancer metastases to the central nervous system, Arch Pathol Lab Med, 127, 1451, 10.5858/2003-127-1451-NSIBCM Lonn, 1994, Intratumoral heterogeneity for amplified genes in human breast carcinoma, Int J Cancer, 58, 40, 10.1002/ijc.2910580108 Pertschuk, 1999, Marked Intratumoral heterogeneity of the proto-oncogene Her-2/neu determined by three different detection systems, Breast J, 5, 369, 10.1046/j.1524-4741.1999.97088.x Glockner, 2002, Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer, Lab Invest, 82, 1419, 10.1097/01.LAB.0000032371.16521.40 Kneuper-Hall, 2003, HER-2/neu intratumoral heterogeneity as analyzed by FISH: a non-apparent entity except in mixed histology tumors, Breast Cancer Res Treat, 82, S98 Montemurro, 2004, Trastuzumab-based combination therapy for breast cancer, Exp Opin Pharmacother, 5, 81, 10.1517/14656566.5.1.81 Gancberg, 2002, Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites, Ann Oncol, 13, 1036, 10.1093/annonc/mdf252 Simon, 2001, Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer, J Natl Cancer Inst, 93, 1141, 10.1093/jnci/93.15.1141 Tanner, 2001, Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer, Cancer Res, 61, 5345 Risio, 2003, HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples, Int J Oncol, 23, 1381